Creo Medical Group (LON:CREO) Releases Earnings Results

Creo Medical Group (LON:CREO) announced its quarterly earnings results on Wednesday. The company reported GBX (2) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%.

Creo Medical Group Stock Down 4.3%

LON:CREO opened at GBX 9.95 on Thursday. The firm has a market cap of £48.34 million, a PE ratio of 9.95 and a beta of 1.56. The company has a 50-day moving average of GBX 12.70 and a 200 day moving average of GBX 12.85. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19. Creo Medical Group has a 1-year low of GBX 9.50 and a 1-year high of GBX 18.50.

Analyst Ratings Changes

Separately, Shore Capital Group restated a “house stock” rating and set a GBX 40 target price on shares of Creo Medical Group in a research note on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.